Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (41-50 of 199) with videos related to

Pageof 20
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 4, 2026
Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancerJustin Battaglini, Maha AlDoughaim, Katie Li, et al.
Academic Radiology|September 24, 2005
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato, Geoffrey R Oxnard, Masha Kocherginsky, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2015
Clinical Implications of Variant ALK FISH Rearrangement PatternsXin Gao, Lynette M Sholl, Mizuki Nishino, et al.
Clinical Lung Cancer|March 15, 2015
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site MutationRussell W Jenkins, Geoffrey R Oxnard, Sheryl Elkin, et al.
CA: a Cancer Journal for Clinicians|November 9, 2020
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directionsMichael L Cheng, Eirini Pectasides, Glenn J Hanna, et al.
Nature Reviews. Clinical Oncology|September 12, 2020
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practiceCharu Aggarwal, Christian D Rolfo, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designJamie E Chaft, Geoffrey R Oxnard, Camelia S Sima, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 3, 2018
Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCRYanan Kuang, Allison O'Connell, Adrian G Sacher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2017
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung CancerGiulia C Leonardi, Geoffrey R Oxnard, Andrea Haas, et al.
Medical Physics|June 12, 2004
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniquesSamuel G Armato, Geoffrey R Oxnard, Heber MacMahon, et al.
Pageof 20

Showing results (41-50 of 199) with videos related to

Sort By:
Pageof 20
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 4, 2026
Real-world adoption of off-label combinations for targeted therapy resistance in non-small cell lung cancerJustin Battaglini, Maha AlDoughaim, Katie Li, et al.
Academic Radiology|September 24, 2005
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scansSamuel G Armato, Geoffrey R Oxnard, Masha Kocherginsky, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 5, 2015
Clinical Implications of Variant ALK FISH Rearrangement PatternsXin Gao, Lynette M Sholl, Mizuki Nishino, et al.
Clinical Lung Cancer|March 15, 2015
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site MutationRussell W Jenkins, Geoffrey R Oxnard, Sheryl Elkin, et al.
CA: a Cancer Journal for Clinicians|November 9, 2020
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directionsMichael L Cheng, Eirini Pectasides, Glenn J Hanna, et al.
Nature Reviews. Clinical Oncology|September 12, 2020
Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practiceCharu Aggarwal, Christian D Rolfo, Geoffrey R Oxnard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2011
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial designJamie E Chaft, Geoffrey R Oxnard, Camelia S Sima, et al.
Methods in Molecular Biology (Clifton, N.J.)|May 3, 2018
Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCRYanan Kuang, Allison O'Connell, Adrian G Sacher, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2017
Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung CancerGiulia C Leonardi, Geoffrey R Oxnard, Andrea Haas, et al.
Medical Physics|June 12, 2004
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniquesSamuel G Armato, Geoffrey R Oxnard, Heber MacMahon, et al.
Pageof 20